Autologous DCs containing the HCA587 protein can induce specific T cell responses in healthy individuals by in vitro stimulation, and HCA587 is a good candidate for the development of a protein-based therapeutic DC tumor vaccine for the treatment of HCC patients. This evidence concerns the gene MAGEC2 and hepatocellular carcinoma.